How much did Karo Pharma achieve in EBIT for the current year?
In the current year, Karo Pharma has achieved an EBIT of 426.36 M SEK.
Karo Pharma EBIT 2024
Karo Pharma EBIT
426.36 M SEK
Ticker
KARO.ST
ISIN
SE0007464888
WKN
A14YW4
In 2024, Karo Pharma's EBIT was 426.36 M SEK, a 17.42% increase from the 363.12 M SEK EBIT recorded in the previous year.
The Karo Pharma EBIT history
| YEAR | EBIT (undefined SEK) |
|---|---|
| 2026e | 656.52 |
| 2025e | 560.76 |
| 2024e | 426.36 |
| 2023e | 363.12 |
| 2022e | 209.1 |
| 2021 | 199.18 |
| 2020 | 250.08 |
| 2019 | 171.79 |
| 2018 | 417.52 |
| 2017 | 96.29 |
| 2016 | 30.94 |
| 2015 | -71.79 |
| 2014 | -63.11 |
| 2013 | -26 |
| 2012 | -99.7 |
| 2011 | -231.2 |
| 2010 | -161.8 |
| 2009 | -157.1 |
| 2008 | -190.7 |
| 2007 | -215.8 |
| 2006 | -132 |
| 2005 | -108.9 |
| 2004 | -114.2 |
| 2003 | -219.2 |
| 2002 | -300.6 |
Karo Pharma Revenue, EBIT, Net Income SE0007464888 · A14YW4
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Karo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Karo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Karo Pharma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Karo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Karo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Karo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Karo Pharma’s growth potential.
Karo Pharma Revenue, EBIT and net profit per share
| Date | Karo Pharma Revenue | Karo Pharma EBIT | Karo Pharma Net Income |
|---|---|---|---|
| 2026e | 4.91 B SEK | 656.52 M SEK | 495.27 M SEK |
| 2025e | 4.86 B SEK | 560.76 M SEK | 198.11 M SEK |
| 2024e | 4.82 B SEK | 426.36 M SEK | 80.83 M SEK |
| 2023e | 4.64 B SEK | 363.12 M SEK | 5.57 M SEK |
| 2022e | 4.32 B SEK | 209.1 M SEK | -69.68 M SEK |
| 2021 | 2.96 B SEK | 199.18 M SEK | -17.45 M SEK |
| 2020 | 2.88 B SEK | 250.08 M SEK | 82.05 M SEK |
| 2019 | 1.9 B SEK | 171.79 M SEK | 8.89 M SEK |
| 2018 | 1.62 B SEK | 417.52 M SEK | 657.38 M SEK |
| 2017 | 657.61 M SEK | 96.29 M SEK | 14.52 M SEK |
| 2016 | 347.26 M SEK | 30.94 M SEK | 95.56 M SEK |
| 2015 | 69.1 M SEK | -71.79 M SEK | -77.63 M SEK |
| 2014 | 30.06 M SEK | -63.11 M SEK | -59.28 M SEK |
| 2013 | 47 M SEK | -26 M SEK | -22.1 M SEK |
| 2012 | 33.2 M SEK | -99.7 M SEK | -98.3 M SEK |
| 2011 | 0 SEK | -231.2 M SEK | -226.6 M SEK |
| 2010 | 0 SEK | -161.8 M SEK | -163.5 M SEK |
| 2009 | 5.9 M SEK | -157.1 M SEK | -154.6 M SEK |
| 2008 | 10.7 M SEK | -190.7 M SEK | -174.8 M SEK |
| 2007 | 7.5 M SEK | -215.8 M SEK | -203.4 M SEK |
| 2006 | 44 M SEK | -132 M SEK | -126.1 M SEK |
| 2005 | 51.9 M SEK | -108.9 M SEK | -111 M SEK |
| 2004 | 39 M SEK | -114.2 M SEK | -107.2 M SEK |
| 2003 | 85.1 M SEK | -219.2 M SEK | -208.7 M SEK |
| 2002 | 177.7 M SEK | -300.6 M SEK | -284.4 M SEK |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2002 | 177.7 M SEK | -300.6 M SEK | -284.4 M SEK |
| 2003 | 85.1 M SEK | -219.2 M SEK | -208.7 M SEK |
| 2004 | 39 M SEK | -114.2 M SEK | -107.2 M SEK |
| 2005 | 51.9 M SEK | -108.9 M SEK | -111 M SEK |
| 2006 | 44 M SEK | -132 M SEK | -126.1 M SEK |
| 2007 | 7.5 M SEK | -215.8 M SEK | -203.4 M SEK |
| 2008 | 10.7 M SEK | -190.7 M SEK | -174.8 M SEK |
| 2009 | 5.9 M SEK | -157.1 M SEK | -154.6 M SEK |
| 2010 | 0 SEK | -161.8 M SEK | -163.5 M SEK |
| 2011 | 0 SEK | -231.2 M SEK | -226.6 M SEK |
| 2012 | 33.2 M SEK | -99.7 M SEK | -98.3 M SEK |
| 2013 | 47 M SEK | -26 M SEK | -22.1 M SEK |
| 2014 | 30.06 M SEK | -63.11 M SEK | -59.28 M SEK |
| 2015 | 69.1 M SEK | -71.79 M SEK | -77.63 M SEK |
| 2016 | 347.26 M SEK | 30.94 M SEK | 95.56 M SEK |
| 2017 | 657.61 M SEK | 96.29 M SEK | 14.52 M SEK |
| 2018 | 1.62 B SEK | 417.52 M SEK | 657.38 M SEK |
| 2019 | 1.9 B SEK | 171.79 M SEK | 8.89 M SEK |
| 2020 | 2.88 B SEK | 250.08 M SEK | 82.05 M SEK |
| 2021 | 2.96 B SEK | 199.18 M SEK | -17.45 M SEK |
| 2022e | 4.32 B SEK | 209.1 M SEK | -69.68 M SEK |
| 2023e | 4.64 B SEK | 363.12 M SEK | 5.57 M SEK |
| 2024e | 4.82 B SEK | 426.36 M SEK | 80.83 M SEK |
| 2025e | 4.86 B SEK | 560.76 M SEK | 198.11 M SEK |
| 2026e | 4.91 B SEK | 656.52 M SEK | 495.27 M SEK |
Karo Pharma stock margins SE0007464888 · A14YW4
The Karo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Karo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Karo Pharma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Karo Pharma's sales revenue. A higher gross margin percentage indicates that the Karo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Karo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Karo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Karo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Karo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Karo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Karo Pharma Margin History
| Karo Pharma Gross margin | Karo Pharma Profit margin | Karo Pharma EBIT margin | Karo Pharma Profit margin |
|---|---|---|---|
| 2026e | 57.62 % | 13.36 % | 10.08 % |
| 2025e | 57.62 % | 11.54 % | 4.08 % |
| 2024e | 57.62 % | 8.84 % | 1.68 % |
| 2023e | 57.62 % | 7.83 % | 0.12 % |
| 2022e | 57.62 % | 4.84 % | -1.61 % |
| 2021 | 57.62 % | 6.73 % | -0.59 % |
| 2020 | 55.34 % | 8.67 % | 2.85 % |
| 2019 | 51.76 % | 9.04 % | 0.47 % |
| 2018 | 58.12 % | 25.85 % | 40.7 % |
| 2017 | 51.99 % | 14.64 % | 2.21 % |
| 2016 | 42.83 % | 8.91 % | 27.52 % |
| 2015 | 41.39 % | -103.89 % | -112.36 % |
| 2014 | 57.62 % | -209.93 % | -197.21 % |
| 2013 | 57.62 % | -55.32 % | -47.02 % |
| 2012 | 57.62 % | -300.3 % | -296.08 % |
| 2011 | 57.62 % | 0 % | 0 % |
| 2010 | 57.62 % | 0 % | 0 % |
| 2009 | 57.62 % | -2,662.71 % | -2,620.34 % |
| 2008 | 57.62 % | -1,782.24 % | -1,633.64 % |
| 2007 | 57.62 % | -2,877.33 % | -2,712 % |
| 2006 | 57.62 % | -300 % | -286.59 % |
| 2005 | 57.62 % | -209.83 % | -213.87 % |
| 2004 | 57.62 % | -292.82 % | -274.87 % |
| 2003 | 57.62 % | -257.58 % | -245.24 % |
| 2002 | 57.62 % | -169.16 % | -160.05 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2002 | 57.62 % | -169.16 % | -160.05 % |
| 2003 | 57.62 % | -257.58 % | -245.24 % |
| 2004 | 57.62 % | -292.82 % | -274.87 % |
| 2005 | 57.62 % | -209.83 % | -213.87 % |
| 2006 | 57.62 % | -300 % | -286.59 % |
| 2007 | 57.62 % | -2,877.33 % | -2,712 % |
| 2008 | 57.62 % | -1,782.24 % | -1,633.64 % |
| 2009 | 57.62 % | -2,662.71 % | -2,620.34 % |
| 2010 | 57.62 % | 0 % | 0 % |
| 2011 | 57.62 % | 0 % | 0 % |
| 2012 | 57.62 % | -300.3 % | -296.08 % |
| 2013 | 57.62 % | -55.32 % | -47.02 % |
| 2014 | 57.62 % | -209.93 % | -197.21 % |
| 2015 | 41.39 % | -103.89 % | -112.36 % |
| 2016 | 42.83 % | 8.91 % | 27.52 % |
| 2017 | 51.99 % | 14.64 % | 2.21 % |
| 2018 | 58.12 % | 25.85 % | 40.7 % |
| 2019 | 51.76 % | 9.04 % | 0.47 % |
| 2020 | 55.34 % | 8.67 % | 2.85 % |
| 2021 | 57.62 % | 6.73 % | -0.59 % |
| 2022e | 57.62 % | 4.84 % | -1.61 % |
| 2023e | 57.62 % | 7.83 % | 0.12 % |
| 2024e | 57.62 % | 8.84 % | 1.68 % |
| 2025e | 57.62 % | 11.54 % | 4.08 % |
| 2026e | 57.62 % | 13.36 % | 10.08 % |
Karo Pharma Aktienanalyse
What does Karo Pharma do?
Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Karo Pharma's EBIT
Karo Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Karo Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Karo Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Karo Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Karo Pharma stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Karo Pharma.
How has the EBIT of Karo Pharma developed in recent years?
The EBIT of Karo Pharma has increased by 17.416% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Karo Pharma?
The EBIT of Karo Pharma is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Karo Pharma pay?
Over the past 12 months, Karo Pharma paid a dividend of 0.27 SEK . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Karo Pharma is expected to pay a dividend of 0.4 SEK.
What is the dividend yield of Karo Pharma?
The current dividend yield of Karo Pharma is 0.45 %.
When does Karo Pharma pay dividends?
Karo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Karo Pharma?
Karo Pharma paid dividends every year for the past 4 years.
What is the dividend of Karo Pharma?
For the upcoming 12 months, dividends amounting to 0.4 SEK are expected. This corresponds to a dividend yield of 0.66 %.
In which sector is Karo Pharma located?
Karo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Karo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Karo Pharma from 5/11/2018 amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.
When did Karo Pharma pay the last dividend?
The last dividend was paid out on 5/11/2018.
What was the dividend of Karo Pharma in the year 2023?
In the year 2023, Karo Pharma distributed 0 SEK as dividends.
In which currency does Karo Pharma pay out the dividend?
The dividends of Karo Pharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Karo Pharma
Our stock analysis for Karo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
